Epilepsy, a chronic neurological disorder, is characterized by recurrent, unprovoked seizures. Despite existing treatment strategies, a significant proportion of patients continue to experience seizures, highlighting the need for improved management approaches. This article provides an update on recent advancements in epilepsy management.
Several new antiepileptic drugs (AEDs) have emerged, offering improved safety and tolerability profiles. Cannabidiol, a non-psychoactive component of cannabis, has shown promise in treating refractory epilepsy. Fenfluramine, previously used as an appetite suppressant, has demonstrated efficacy in reducing seizure frequency in Dravet syndrome.
Neuromodulation, involving the alteration of nerve activity through targeted delivery of a stimulus, has gained traction in epilepsy management. Deep brain stimulation (DBS), vagus nerve stimulation (VNS), and responsive neurostimulation (RNS) are FDA-approved neuromodulation therapies for epilepsy. These techniques offer an alternative for patients who are not candidates for surgery or who have not responded to pharmacological treatments.
Surgical intervention remains a viable option for patients with drug-resistant epilepsy. Laser interstitial thermal therapy (LITT) is a minimally invasive surgical procedure that ablates seizure foci, reducing seizure frequency. Stereotactic radiosurgery is another non-invasive technique that allows precise targeting of epileptogenic zones.
Advancements in genetic testing have led to the identification of numerous epilepsy-associated genes, enabling precision medicine approaches. These advancements can lead to personalized treatment strategies, potentially improving outcomes for patients with genetically defined epilepsies.
The field of epilepsy management is rapidly evolving with the emergence of new pharmacological treatments, neuromodulation techniques, surgical interventions, and advancements in genetic testing. These developments offer promising avenues for improving seizure control and patient quality of life. Continued research and clinical trials are essential to validate these approaches and optimize their integration into clinical practice.
1.
A US health panel advises starting mammograms at age 40 rather than 50.
2.
TULSA Is Effective in Long-Term Prostate Cancer Control.
3.
J. Craig Venter, Who Won the Race to Sequence the Human Genome, Dies at 79
4.
In Sickle Cell Disease, Lovo-Cel is "Life-Changing, Transformative.".
5.
How Social Determinants of Health Are Linked to Outcomes in Multiple Myeloma
1.
Molecular Matching for Individualized Blood-Disorder Therapy
2.
Everything You Need To Know About Melanoma Choroid: Causes, Symptoms, and Treatment
3.
Drug Safety Surveillance of Long-Term Medication Effects in Cancer Survivorship
4.
HPV-Related Cervical Cancer: Advances in Screening, Preventiofn & Treatment
5.
Early Diagnosis of Lung Cancer Through Emerging Biomarkers
1.
International Cancer Conference
2.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
3.
International Cancer Conference
4.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Current Scenario of Cancer- The Incidence of Cancer in Men
2.
First Line Combination Therapy- The Overall Survival Data in NSCLC Patients
3.
L858R Mutation- An Overview of Retrospective Cohort Study in Advanced NSCLC Patients
4.
Redefining Treatment Pathways in Relapsed/Refractory Adult B-Cell ALL
5.
An Eagles View - Evidence-based discussion on Iron Deficiency Anemia
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation